About the conference

With multidrug resistance ever-increasing on a worldwide scale, advances in antibacterial development have never been more important. This year's conference will consist of a variety of different case study focused presentations featuring real life success stories and failures enabling attendees to learn from and discuss with key industry professionals on challenges facing this rapidly-evolving field.

Senior industry executives in the field will present on their experiences of antibiotic resistance and development of new antibacterial agents.

Key areas to be discussed in this year's conference are:

• Therapies to overcome microbial resistance
• Antimicrobial resistant pathogens
• Gram Positive and Gram Negative bacteria infection treatments
• Cell division inhibitors
• Microbiomes as basic defence mechanisms
• Antibody based strategies
• Regulatory requirements for new antimicrobials
• Government incentive schemes 

Interested in speaking at the conference?  Contact the Conference Producer.

For sponsorship and exhibition opportunities, Contact our Sponsorship Department

Speakers for this year's event include:

Ron Gladue, Research Fellow, Pfizer

Lynn Miesel, Senior Research Fellow, Merck

Neil Ryder, Executive Director, Microbial Vaccines, Novartis

Chris Longshaw, Associate Director of Microbiology, Astellas

Sheo Singh, Senior Investigator, Merck

Mick Gwynn, Director, Microbiology & Infectious Diseases, GlaxoSmithKline

Markus Heep, Principal Medical Scientific Expert, Novartis

Amita Joshi, Sr Research Immunologist, Microbial Vaccines, Merck

Justin Montgomery, Senior Principal Scientist, Pfizer

Bret Sellman, Principal Scientist, Medimmune

Richard Bax, Senior Partner, Transcrip Partners

Christian Felter, Associate Director, Medical Affairs, Astellas

Alice Erwin, Research Fellow, Antibacterial Drug Discovery, Vertex Pharmaceuticals

Neil Woodford, Acting Director, Health Protection Agency

Malcolm Page, Head of Biology, Basilea Pharmaceutica

Barry Hafkin, CMO, Affininum Pharmaceuticals

Lloyd Payne, CEO, Euprotec

Barry Eisenstein, Senior VP, Scientific Affairs, Cubist Pharmaceuticals

Anthony Coates, Professor of Medical Microbiology, St George's University London

Organisations represented at our previous Superbugs and Superdrugs conferences include:

Delegates at our 2011 Superbugs & Superdrugs Conference came from across the world... Join the wide range of high-level delegates at our event in 2012..

• Pfizer
• GlaxoSmithKline
• Sanofi-Aventis
• Novartis
• Boehringer-Ingelheim
• AstraZeneca
• Merck
• Vertex
• Boehringer-Ingelheim
• Queen Mary University London
• University of Oxford
• Basilea Pharmaceuticals
• Affinium Pharmaceuticals
• Novexel
• Quotient Bioresearch
• TranScrip Partners
• University of Leeds
• Rib-X Pharmaceuticals
• European Commission
• Kenta Biotech
• PolyMedix
• Theravance Cubix